BenevolentAI Investor Day Presentation Deck

UC and CD biopsies responsive to pharmacological intervention % RIPK2 (of DMSO control) c) % RIPK2 (of DMSO control) % cytokine (of DMSO control) 150- 100- 50- -12 1501 O 100- 50- -12 150-₁ 100- 50- [PROTAC 6] log (M) PROTAC 6 PROTAC 7 -10 -6 [compound] log (M) CD Patient Biopsies 暅 6 hours 24 hours -8 0.05 IL-1B IL-6 TNFa PROTAC 6 (nM) b) % cytokines (of DMSO control) d) % TNFa (of DMSO control) % cytokine (of DMSO control) 150 100- 50- 0- -50- -12 150 100- 50- -50- -12 200₁ 150- 100- 50- HOH O -6 [PROTAC 6] log (M) -10 PROTAC 6 PROTAC 7 -10 -6 [compound] log (M) UC Patient Biopsies 0.05 0.5 TNFa IL-6 IL-8 IL-10 IL-18 IL-1B IL-6 TNFa PROTAC 6 (nM) Benevolent 55

View entire presentation